Literature DB >> 33751856

MET transcriptional regulator/serine peptidase inhibitor kunitz type 1 panel operating through HGF/c-MET axis as a prognostic signature in pan-cancer.

Yi Xiang1, Bishan Liang1, Yu Jiang1, Fei Sun1, Yang Zhao1, Qijing Wu1, Xingbin Hu1, Yajing Liu1, Qiong Huang1, Wangjun Liao1, Zhiqi Yao1, Shaowei Li1, Min Shi1.   

Abstract

Dysregulations in transcription factors (TFs) and their genetic products play important roles in tumorigenesis, tumor progression and metastasis. However, prognostic value of the transcriptional regulatory networks in different cancers has not been investigated in depth. The purpose of our study was to identify and validate a potential predictive signature that combines TFs and their regulatory products in eight solid tumors. We used bioinformatics analysis to identify MET Transcriptional Regulator (MACC1) and Serine Peptidase Inhibitor Kunitz Type 1 (SPINT1) as candidate TFs with the respective downstream regulatory proteins for patient prognosis in pan-cancer. Subsequent molecular analysis of clinical gastric cancer tissue samples further verified the negative correlation between MACC1 and SPINT1. Further, we showed that mechanistically, MACC1/SPINT1 mediated the pro-HGF proteolysis and c-Met phosphorylation in HGF/c-MET signaling pathway. Kaplan-Meier plots and receiver operating characteristics analysis revealed that the two-gene signature combining MACC1 with SPINT1 was effective in predicting survival in all eight cancer cohorts tested. In conclusion, our study clarified the regulatory relationship between MACC1 and SPINT1 in the context of the HGF/c-MET signaling pathway and determined MACC1/SPINT1 panel as a valuable signature for the prediction of prognosis in patients for multiple solid cancer types.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HGF/c-Met axis; MACC1; SPINT1; cell proliferation; pan-cancer; prognosis

Year:  2021        PMID: 33751856      PMCID: PMC7982633          DOI: 10.1002/cam4.3834

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  66 in total

1.  Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN.

Authors:  Domènec Farré; Romà Roset; Mario Huerta; José E Adsuara; Llorenç Roselló; M Mar Albà; Xavier Messeguer
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

Review 3.  New Binding Sites, New Opportunities for GPCR Drug Discovery.

Authors:  H C Stephen Chan; Yi Li; Thamani Dahoun; Horst Vogel; Shuguang Yuan
Journal:  Trends Biochem Sci       Date:  2019-01-03       Impact factor: 13.807

Review 4.  Eukaryotic core promoters and the functional basis of transcription initiation.

Authors:  Vanja Haberle; Alexander Stark
Journal:  Nat Rev Mol Cell Biol       Date:  2018-10       Impact factor: 94.444

5.  Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.

Authors:  Eunice L Kwak; Leanne G Ahronian; Giulia Siravegna; Benedetta Mussolin; Darrell R Borger; Jason T Godfrey; Nicholas A Jessop; Jeffrey W Clark; Lawrence S Blaszkowsky; David P Ryan; Jochen K Lennerz; A John Iafrate; Alberto Bardelli; Theodore S Hong; Ryan B Corcoran
Journal:  Cancer Discov       Date:  2015-10-02       Impact factor: 39.397

6.  Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.

Authors:  Hideko Isozaki; Eiki Ichihara; Nagio Takigawa; Kadoaki Ohashi; Nobuaki Ochi; Masayuki Yasugi; Takashi Ninomiya; Hiromichi Yamane; Katsuyuki Hotta; Katsuya Sakai; Kunio Matsumoto; Shinobu Hosokawa; Akihiro Bessho; Toshiaki Sendo; Mitsune Tanimoto; Katsuyuki Kiura
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

7.  ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.

Authors:  Jaana M Kauppinen; Veli-Matti Kosma; Ylermi Soini; Reijo Sironen; Minna Nissinen; Timo K Nykopp; Vesa Kärjä; Matti Eskelinen; Vesa Kataja; Arto Mannermaa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-17       Impact factor: 4.254

8.  NCBI GEO: archive for high-throughput functional genomic data.

Authors:  Tanya Barrett; Dennis B Troup; Stephen E Wilhite; Pierre Ledoux; Dmitry Rudnev; Carlos Evangelista; Irene F Kim; Alexandra Soboleva; Maxim Tomashevsky; Kimberly A Marshall; Katherine H Phillippy; Patti M Sherman; Rolf N Muertter; Ron Edgar
Journal:  Nucleic Acids Res       Date:  2008-10-21       Impact factor: 16.971

9.  MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.

Authors:  Ulrike Stein; Wolfgang Walther; Franziska Arlt; Holger Schwabe; Janice Smith; Iduna Fichtner; Walter Birchmeier; Peter M Schlag
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

10.  Loss of hepatocyte growth factor activator inhibitor type 1 participates in metastatic spreading of human pancreatic cancer cells in a mouse orthotopic transplantation model.

Authors:  Jingjia Ye; Makiko Kawaguchi; Yukihiro Haruyama; Ai Kanemaru; Tsuyoshi Fukushima; Koji Yamamoto; Chen-Yong Lin; Hiroaki Kataoka
Journal:  Cancer Sci       Date:  2013-11-25       Impact factor: 6.716

View more
  3 in total

1.  Alpha-fetoprotein can promote gastric cancer progression via upregulation of metastasis-associated colon cancer 1.

Authors:  Xiang Mao; Jun Wang; Fen Luo
Journal:  Oncol Lett       Date:  2022-01-18       Impact factor: 2.967

2.  The Relationship between MACC1/c-Met/Cyclin D1 Axis Expression and Prognosis in ESCC.

Authors:  Yan Shi; Meng-Yan Li; Hui Wang; Chao Li; Wen-Ying Liu; Yong-Mei Gao; Bo Wang; Jia-Wei Song; Yu-Qing Ma
Journal:  Anal Cell Pathol (Amst)       Date:  2022-02-22       Impact factor: 2.916

3.  MACC1 Promotes the Progression and Is a Novel Biomarker for Predicting Immunotherapy Response in Colorectal Cancer.

Authors:  Man Xiong; Mingsen Wang; Youhong Yan; Xiaowu Chen; Wanwei Guo; Ming Xu; Shaoyan Guo; Yeyang Wang
Journal:  J Oncol       Date:  2022-07-14       Impact factor: 4.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.